Progressive Care Inc. (OTCQB: RXMD)
Progressive Care Inc. (OTCQB: RXMD) is a health services organization based in Florida that offers personalized healthcare services and technology that supports the managed healthcare industry. Through its subsidiaries, Progressive Care provides Third-Party Administration (TPA), data management and analytics, COVID-19 diagnostics and vaccinations, 340B contracted pharmacy services, compounded medications, tele-pharmacy services, dispensing of anti-retroviral medications, medication therapy management (MTM), long-term care facility-targeted prescription medications, and health practice risk management.
The company collaborates with various healthcare organizations such as managed care organizations (MCOs), management services organizations (MSOs), accountable care organizations (ACOs), primary care providers, Medicare Advantage plans, Medicaid, commercial payors, pharmaceutical manufacturers, and distributors to enhance patient and provider engagement while improving the lives of patients with chronic diseases. Progressive Care offers a wide range of innovative solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs.
Progressive Care currently operates four pharmacies in Florida, which generate the majority of its revenue. Pharmacy revenue is derived from dispensing medications, third-party administrative services to 340B-covered entities, and MTM services. The company also provides customized management, patient health risk reviews, and free same- and next-day delivery. Its focus is on complex chronic diseases that require multiyear or lifelong therapy, driving recurring revenue and sustainable growth. Progressive Care’s pharmacy revenue growth stems from its expanding breadth of services, new drugs coming to market, new indications for existing drugs, volume growth with current clients, and addition of new customers resulting from its emphasis on higher patient engagement, free delivery to the patient, and clinical expertise.
With licenses in 14 states, Progressive Care is poised for national expansion. The company anticipates revenue growth by signing new contract pharmacy service and data management contracts with 340B-covered entities, expanding data management and analytics services to healthcare organizations, and potential acquisitions.
Progressive Care’s wholly-owned subsidiaries provide services to client organizations and patients.
PharmcoRx, a full-service pharmacy, provides a complete healthcare ecosystem with services such as medication therapy management, rapid COVID-19 testing and vaccines, contactless medication delivery, Smart-Pack Unit Dosing packaging, custom compound medications, specialty medications, hospital transition pharmacy services, medication adherence monitoring, medication adherence risk management, and drug cost containment. PharmcoRx Pharmacy is a contracted pharmacy services provider for 340B-covered entities under the 340B Drug Discount Pricing Program.
ClearMetrX, a wholly-owned data management company, offers services that support healthcare organizations across the country. In September 2022, ClearMetrX launched the 340MetrX Platform, a software product developed by ClearMetrX that provides 340B-covered entities with data insights to effectively operate and maximize the benefits of the 340B program. 340MetrX supplies data access and delivers actionable insights that providers and support organizations can use to improve their practices and patient care. Its TPA services include management of wholesale accounts and contract pharmacies, patient eligibility with regard to the 340B drug program, development and review of 340B policies and procedures, and management of receivables.
According to an industry report by global consulting firm Berkeley Research Group, gross sales across the 340B drug program were valued at $116 billion in 2021 and are projected to grow to $280 billion by 2026, achieving a CAGR of more than 19% over the period.
The 340B drug pricing program allows eligible healthcare clinics and hospitals (the covered entities) to purchase outpatient drugs at a 20-50 percent discount to treat low-income, uninsured, or underinsured populations. The program’s forecast growth is expected to benefit Progressive care’s business of providing 340B program services to covered entities through the nationwide expansion of ClearMetrX, its third-party administration and data-management business.
Charles M. Fernandez is CEO and Chairman of the Board of Directors of Progressive Care. Mr. Fernandez is also the Executive Chairman and CEO of NextPlat Corp. (NASDAQ: NXPL) and has over 30 years of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. In 2008, he joined Fairholme Capital Management. As president, he co-managed all three Fairholme funds and was commended for bringing in a $2 billion gain for shareholders. Throughout his impressive career in media, pharmaceuticals, healthcare, finance and technology, Mr. Fernandez has participated in more than 100 significant mergers, acquisitions and product development projects. He was the founder, chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK) which was successfully sold to Smartrac, a leading developer, manufacturer and supplier of RFID and Internet of Things (“IoT”) solutions and a unit of Avery Dennison Corporation (NYSE: AVY).
Other top management team members include Chief Operating Officer Birute Norkute, Chief Financial Officer Cecile Munnik, and Pamela Roberts, who serves as the company’s Pharmacist in Charge.